Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness

Molecular Pharmaceutics

Volumn 13, Issue 3, 2016, Pages 1073-1080

  Xie, Ying ^a   Wehrkamp, Cody J ^b   Li, Jing ^a   Wang, Yan ^a   Wang, Yazhe ^a   Mott, Justin L ^b   Oupický, David ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cholangiocarcinoma; CXCR4; microRNA; poly(amido amine); polyplexes

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; MICRORNA 200C; POLYAMIDOAMINE; POLYCATION; CXCR4 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; MESSENGER RNA; MICRORNA; MIRN200 MICRORNA, HUMAN; PLERIXAFOR; POLYAMINE;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; PRIORITY JOURNAL; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BILE DUCT NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CHOLANGIOCARCINOMA; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HETEROCYCLIC COMPOUNDS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; POLYAMINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84960172804     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00894     Document Type: Article

References (44)

1. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004, 116, 281-297 10.1016/S0092-8674(04)00045-5
2. Li, Z.; Rana, T. M. Therapeutic targeting of microRNAs: current status and future challenges Nat. Rev. Drug Discovery 2014, 13, 622-638 10.1038/nrd4359
3. Grimson, A.; Farh, K. K.-H.; Johnston, W. K.; Garrett-Engele, P.; Lim, L. P.; Bartel, D. P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing Mol. Cell 2007, 27, 91-105 10.1016/j.molcel.2007.06.017
4. Lewis, B. P.; Burge, C. B.; Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 2005, 120, 15-20 10.1016/j.cell.2004.12.035
5. Calin, G. A.; Croce, C. M. MicroRNA signatures in human cancers Nat. Rev. Cancer 2006, 6, 857-866 10.1038/nrc1997
6. Esquela-Kerscher, A.; Slack, F. J. Oncomirs-microRNAs with a role in cancer Nat. Rev. Cancer 2006, 6, 259-269 10.1038/nrc1840
7. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer Nat. Rev. Genet. 2009, 10, 704-714 10.1038/nrg2634
8. Kasinski, A. L.; Slack, F. J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nat. Rev. Cancer 2011, 11, 849-864 10.1038/nrc3166
9. Patel, T. Cholangiocarcinoma-controversies and challenges Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 189-200 10.1038/nrgastro.2011.20
10. Khan, S. A.; Thomas, H. C.; Davidson, B. R.; Taylor-Robinson, S. D. Cholangiocarcinoma Lancet 2005, 366, 1303-1314 10.1016/S0140-6736(05)67530-7
11. Rizvi, S.; Gores, G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma Gastroenterology 2013, 145, 1215-1229 10.1053/j.gastro.2013.10.013
12. Okuda, K.; Nakanuma, Y.; Miyazaki, M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment J. Gastroenterol. Hepatol. 2002, 17, 1056-1063 10.1046/j.1440-1746.2002.02780.x
13. Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Oncogene 2013, 32, 4861-4870 10.1038/onc.2012.617
14. Mott, J. L. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia Hepatology 2009, 50, 630-637 10.1002/hep.23010
15. Razumilava, N.; Bronk, S. F.; Smoot, R. L.; Fingas, C. D.; Werneburg, N. W.; Roberts, L. R.; Mott, J. L. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma Hepatology 2012, 55, 465-475 10.1002/hep.24698
16. Meng, F.; Henson, R.; Lang, M.; Wehbe, H.; Maheshwari, S.; Mendell, J. T.; Jiang, J.; Schmittgen, T. D.; Patel, T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines Gastroenterology 2006, 130, 2113-2129 10.1053/j.gastro.2006.02.057
17. Selaru, F. M.; Olaru, A. V.; Kan, T.; David, S.; Cheng, Y.; Mori, Y.; Yang, J.; Paun, B.; Jin, Z.; Agarwal, R. et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3 Hepatology 2009, 49, 1595-1601 10.1002/hep.22838
18. Chusorn, P.; Namwat, N.; Loilome, W.; Techasen, A.; Pairojkul, C.; Khuntikeo, N.; Dechakhamphu, A.; Talabnin, C.; Chan-On, W.; Ong, C. et al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis Tumor Biol. 2013, 34, 1579-1588 10.1007/s13277-013-0688-0
19. Oishi, N.; Kumar, M. R.; Roessler, S.; Ji, J.; Forgues, M.; Budhu, A.; Zhao, X.; Andersen, J. B.; Ye, Q. H.; Jia, H. L. et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma Hepatology 2012, 56, 1792-1803 10.1002/hep.25890
20. Li, B.; Han, Q.; Zhu, Y.; Yu, Y.; Wang, J.; Jiang, X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist FEBS J. 2012, 279, 2393-2398 10.1111/j.1742-4658.2012.08618.x
21. Chen, Y.; Gao, D.-Y.; Huang, L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies Adv. Drug Delivery Rev. 2015, 81, 128-141 10.1016/j.addr.2014.05.009
22. Cheng, C. J.; Saltzman, W. M. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing Mol. Pharmaceutics 2012, 9, 1481-1488 10.1021/mp300081s
23. Zhang, Y.; Wang, Z.; Gemeinhart, R. A. Progress in microRNA delivery J. Controlled Release 2013, 172, 962-974 10.1016/j.jconrel.2013.09.015
24. Li, J.; Wang, Y.; Zhu, Y.; Oupický, D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment J. Controlled Release 2013, 172, 589-600 10.1016/j.jconrel.2013.04.010
25. Kumar, V.; Mondal, G.; Slavik, P.; Rachagani, S.; Batra, S. K.; Mahato, R. I. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer Mol. Pharmaceutics 2015, 12, 1289-98 10.1021/mp500847s
26. Devulapally, R.; Sekar, N. M.; Sekar, T. V.; Foygel, K.; Massoud, T. F.; Willmann, J. r. K.; Paulmurugan, R. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy ACS Nano 2015, 9, 2290-2302 10.1021/nn507465d
27. Chiou, G.-Y.; Cherng, J.-Y.; Hsu, H.-S.; Wang, M.-L.; Tsai, C.-M.; Lu, K.-H.; Chien, Y.; Hung, S.-C.; Chen, Y.-W.; Wong, C.-I.; Tseng, L.-M.; Huang, P.-I.; Yu, C.-C.; Hsu, W.-H.; Chiou, S.-H. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma J. Controlled Release 2012, 159, 240-250 10.1016/j.jconrel.2012.01.014
28. Zhao, H.; Guo, L.; Zhao, H.; Zhao, J.; Weng, H.; Zhao, B. CXCR4 over-expression and survival in cancer: A system review and meta-analysis Oncotarget 2015, 6, 5022-40 10.18632/oncotarget.3217
29. Tan, X.-Y.; Chang, S.; Liu, W.; Tang, H.-H. Silencing of CXCR4 Inhibits Tumor Cell Proliferation and Neural Invasion in Human Hilar Cholangiocarcinoma Gut Liver 2014, 8, 196-204 10.5009/gnl.2014.8.2.196
30. Ohira, S.; Sasaki, M.; Harada, K.; Sato, Y.; Zen, Y.; Isse, K.; Kozaka, K.; Ishikawa, A.; Oda, K.; Nimura, Y. et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-α and stromal-derived factor-1 released in stroma Am. J. Pathol. 2006, 168, 1155-1168 10.2353/ajpath.2006.050204
31. Leelawat, K.; Keeratichamroen, S.; Leelawat, S.; Tohtong, R. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2 Oncol. Lett. 2013, 6, 1439-1446 10.3892/ol.2013.1587
32. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N. et al. Involvement of chemokine receptors in breast cancer metastasis Nature 2001, 410, 50-56 10.1038/35065016
33. Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M. Z. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1/CXCR4 Axis Stem Cells 2005, 23, 879-894 10.1634/stemcells.2004-0342
34. Smith, M. C.; Luker, K. E.; Garbow, J. R.; Prior, J. L.; Jackson, E.; Piwnica-Worms, D.; Luker, G. D. CXCR4 regulates growth of both primary and metastatic breast cancer Cancer Res. 2004, 64, 8604-8612 10.1158/0008-5472.CAN-04-1844
35. Balkwill, F. Cancer and the chemokine network Nat. Rev. Cancer 2004, 4, 540-550 10.1038/nrc1388
36. Guo, P.; You, J.-O.; Yang, J.; Jia, D.; Moses, M. A.; Auguste, D. T. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade Mol. Pharmaceutics 2014, 11, 755-765 10.1021/mp4004699
37. Li, J.; Zhu, Y.; Hazeldine, S. T.; Li, C.; Oupicky, D. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion Angew. Chem., Int. Ed. 2012, 51, 8740-3 10.1002/anie.201203463
38. Wang, Y.; Hazeldine, S. T.; Li, J.; Oupicky, D. Development of Functional Poly(amido amine) CXCR4 Antagonists with the Ability to Mobilize Leukocytes and Deliver Nucleic Acids Adv. Healthcare Mater. 2015, 4, 729-38 10.1002/adhm.201400608
39. Wang, Y.; Li, J.; Chen, Y.; Oupicky, D. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes Biomater. Sci. 2015, 3, 1114-23 10.1039/C5BM00003C
40. Li, J.; Oupicky, D. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor Biomaterials 2014, 35, 5572-5579 10.1016/j.biomaterials.2014.03.047
41. Miyagiwa, M.; Ichida, T.; Tokiwa, T.; Sato, J.; Sasaki, H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium In Vitro Cell. Dev. Biol. 1989, 25, 503-510 10.1007/BF02623562
42. Wehrkamp, C. J.; Gutwein, A. R.; Natarajan, S. K.; Phillippi, M. A.; Mott, J. L. XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells PLoS One 2014, 9, e90238 10.1371/journal.pone.0090238
43. Gregory, P. A.; Bert, A. G.; Paterson, E. L.; Barry, S. C.; Tsykin, A.; Farshid, G.; Vadas, M. A.; Khew-Goodall, Y.; Goodall, G. J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 Nat. Cell Biol. 2008, 10, 593-601 10.1038/ncb1722
44. Korpal, M.; Lee, E. S.; Hu, G.; Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2 J. Biol. Chem. 2008, 283, 14910-14914 10.1074/jbc.C800074200